Thu, January 12, 2023
Wed, January 11, 2023
Tue, January 10, 2023
Mon, January 9, 2023
Sun, January 8, 2023
Fri, January 6, 2023

Judah Frommer Maintained (SRPT) at Hold with Increased Target to $114 on, Jan 10th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-114-on-jan-10th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $101 to $114 on, Jan 10th, 2023.

Judah has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Judah's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022


These are the ratings of the 6 analyists that currently disagree with Judah


  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022

Publication Contributing Sources